This is how AI will shape drug discovery
AI software is expanding the universe of screenable compounds and will deliver higher hit rates as compounds move through the pharma value chain.
AI software is expanding the universe of screenable compounds and will deliver higher hit rates as compounds move through the pharma value chain.
B Capital Group Partner Gavin Teo said tax reform and a more liberal FDA are helping to make technologies supporting drug research and development more attractive to investors.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.